Travere Therapeutics Raises PT to $34 on Strong Q2, FDA Catalysts Ahead.

Citi raises Travere Therapeutics (TVTX) PT to $34 from $32, maintaining a Buy rating on the shares. The firm sees significant upside potential due to two near-term FDA action dates for Travere. Q2 2025 financial results showed a revenue of $114.4 million, up from $54.1 million in Q2 2024, driven by a 165% YoY growth in US net product sales of FILSPARI.

Citi has recently raised its price target for Travere Therapeutics (TVTX) to $34 from $32, while maintaining a Buy rating on the shares. The firm sees significant upside potential for the company due to two near-term FDA action dates. Travere Therapeutics reported its Q2 2025 financial results, showing a revenue of $114.4 million, up from $54.1 million in Q2 2024. This growth was driven by a 165% year-over-year increase in US net product sales of FILSPARI, which reached $71.9 million [2].

Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases. The company's flagship product, FILSPARI, has shown promising growth, with shares trading up ~81% since the implementation of its restructuring plan [3]. The company's shares have surged by approximately 81% since the restructuring plan, reflecting the positive impact of strategic initiatives [3].

In Q2 2025, Travere Therapeutics reported total revenue of $114.45 million, a substantial 111.5% increase compared to $54.12 million in the same period of the prior year. The company narrowed its net loss to $-12.76 million, an 81.9% reduction from the $-70.41 million loss in Q2 2024 [3]. The company is also making progress in regulatory milestones, with the potential second indication for FILSPARI in focal segmental glomerulosclerosis (FSGS), with the sNDA review advancing as expected and a PDUFA date of January 13, 2026 [3].

The company is positioned for continued revenue growth, with near-term catalysts including potential REMS modifications and a forthcoming FSGS indication. Management remains confident in their strategic direction, highlighting robust financials, pipeline progress, and the anticipated impact of regulatory milestones through year-end and into 2026 [3].

References:
[1] https://ir.travere.com/overview/default.aspx
[2] https://finance.yahoo.com/news/citi-lifts-travere-therapeutics-tvtx-034110373.html
[3] https://www.ainvest.com/news/travere-therapeutics-sees-promising-growth-filspari-2508/